Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.

Cancer chemotherapy and pharmacology - 1 Oct 2015

Otsuka Kyoko, Hata Akito, Takeshita Jumpei, Okuda Chiyuki, Kaji Reiko, Masago Katsuhiro, Fujita Shiro, Katakami Nobuyuki

Abstract excerpt

BACKGROUND: Efficacies of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) rechallenge have been demonstrated in EGFR-mutant non-small cell lung cancer (NSCLC). However, their efficacies were only moderate. Some preclinical studies suggested synergistic effects of bevacizumab to EGFR-TKI in TKI-resistant models. METHODS: We retrospectively evaluated clinical efficacy and safety of EGFR-TKI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Drug Monitoring

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Quinazolines

Source

Identifiers

PMID: 26349474
DOI: 10.1007/s00280-015-2867-8

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.PMID 26349474Read ↗

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.Semantic proximity Read ↗

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations.Semantic proximity Read ↗

EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.Semantic proximity Read ↗

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).Semantic proximity Read ↗

Furmonertinib rechallenge for first-line third-generation EGFR TKI-resistant EGFR-mutant NSCLC: A retrospective propensity score-matched cohort study.Semantic proximity Read ↗

Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy.Semantic proximity Read ↗

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.Semantic proximity Read ↗

Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series.Semantic proximity Read ↗

Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.Semantic proximity Read ↗

Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?Semantic proximity Read ↗

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.